Topic:

Venture Capital

Latest Headlines

Latest Headlines

Little Neos gets a $20M bankroll to prep ADHD drugs for FDA review

Texas-based Neos Therapeutics has rounded up $20.6 million to bankroll their late-stage regulatory work on extended-release formulations of a slate of ADHD drugs that is now being served up to regulators for review.

Biotech bonanza helps Bessemer roll out a $1.6B venture fund

Bessemer Venture Partners is rolling out a global fund with $1.6 billion to invest in a range of new technologies--including biotech.

Transcriptic snags $8.5M to add capabilities at robot-run lab

Robot-run lab startup Transcriptic has raised $8.5 million in a Series A round to buy more equipment and expand its service offering. The round once again attracted a clutch of big name, Big Data-focused Silicon Valley VC funds, including Data Collective and IA Ventures.

Quantum Genomics sees stock soar after oversubscribed IPO

Strong interest from individuals in France has helped Quantum Genomics blast past its IPO targets. The open-price offering was almost 15 times oversubscribed as individuals flocked to the biotech to finance the advance of its blood pressure drug into clinical proof-of-concept trials.

Novartis leads a $28M round for rare disease biotech Merganser

Pennsylvania's Merganser Biotech raised a $28 million A round with the help of Novartis Venture Fund, paying the company's way as it homes in on iron-related diseases.

Star scientist Peter Mueller gets $28M war chest to advance R&D at Pronutria

Last November the upstart biotech Pronutria Biosciences landed Peter Mueller as its R&D chief shortly after he stepped aside from his starring role as research chief for Vertex. And now Pronutria has landed $28 million in financing to advance its drug development efforts.

Low-profile biotech gets $30M, new CEO and new home for PhIII atrial fib effort

A low-profile biotech in Cleveland landed a $30 million B round with the help of a new group of prominent venture backers and has been given a new CEO, a new home in La Jolla and a continuing mission to develop a drug for atrial fibrillation that has quietly moved to the threshold of a Phase III program.

Biotech boom drives blockbuster VC investments in Boston, San Francisco

The venture boom that funneled billions of dollars into life sciences companies last year included a big surge in first-time deals, according to a fresh analysis of the numbers for 2014. And the boom in venture investing looks set to continue well into 2015.

Lux Capital raises $350M to expand its startup portfolio

Lux Capital, a New York venture investor, put together a $350 million fourth fund, cash that will help bankroll startups in energy, technology and biotech.

Japan's Daiwa establishes major biotech fund for home and Taiwan

SINGAPORE-- A Japan-based securities firm said it has established the nation's largest fund in the biotech field, seeding it with $83.6 million to support startup biotech companies at home and in Taiwan.